214 related articles for article (PubMed ID: 19840692)
1. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
Talbird SE; Brogan AJ; Winiarski AP
Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
Risebrough NA; Bowles SK; Simor AE; McGeer A; Oh PI
J Am Geriatr Soc; 2005 Mar; 53(3):444-51. PubMed ID: 15743287
[TBL] [Abstract][Full Text] [Related]
3. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
Rothberg MB; Fisher D; Kelly B; Rose DN
Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
[TBL] [Abstract][Full Text] [Related]
4. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States.
Talbird SE; Brogan AJ; Winiarski AP; Sander B
Am J Health Syst Pharm; 2009 Mar; 66(5):469-80. PubMed ID: 19233995
[TBL] [Abstract][Full Text] [Related]
8. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
[TBL] [Abstract][Full Text] [Related]
10. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
Sander B; Hayden FG; Gyldmark M; Garrison LP
Pharmacoeconomics; 2006; 24(4):373-86. PubMed ID: 16605283
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.
Postma MJ; Beardsworth P; Wilschut JC
J Med Econ; 2008; 11(4):743-68. PubMed ID: 19450079
[TBL] [Abstract][Full Text] [Related]
12. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
Hayden FG; Belshe R; Villanueva C; Lanno R; Hughes C; Small I; Dutkowski R; Ward P; Carr J
J Infect Dis; 2004 Feb; 189(3):440-9. PubMed ID: 14745701
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
15. Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis.
Shen K; Xiong T; Tan SC; Wu J
PLoS One; 2016; 11(4):e0153664. PubMed ID: 27082431
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
[TBL] [Abstract][Full Text] [Related]
17. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
Lugnér AK; Mylius SD; Wallinga J
Health Econ; 2010 May; 19(5):518-31. PubMed ID: 19382106
[TBL] [Abstract][Full Text] [Related]
18. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada.
Skowronski DM; Woolcott JC; Tweed SA; Brunham RC; Marra F
Vaccine; 2006 May; 24(19):4222-32. PubMed ID: 16423432
[TBL] [Abstract][Full Text] [Related]
19. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
[TBL] [Abstract][Full Text] [Related]
20. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation.
Tappenden P; Jackson R; Cooper K; Rees A; Simpson E; Read R; Nicholson K
Health Technol Assess; 2009 Feb; 13(11):iii, ix-xii, 1-246. PubMed ID: 19215705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]